摘要
肝纤维化是各种病因引起的慢性肝病进展至肝硬化的必经阶段,迄今为止临床上尚缺乏特异性针对肝纤维化的有效逆转或阻止其进展的药物.肝纤维化是一个由多种细胞因子和分子途径参与的复杂病理变化,深入探究肝纤维化的细胞分子机制从而发掘出特异性的抗纤维化治疗靶点并将其转化为临床治疗具有重大意义.
Hepatic fibrosis is a characteristic consequence of multiple chronic liver injuries. However, there are currently no specific drugs that can effectively reverse or prevent liver fibrosis progression. Liver fibrosis is a complex pathological process attributable to a variety of cytokines and molecular pathways. Therefore, further exploring the cellular and molecular mechanisms of liver fibrosis, unearthing specific anti-fibrosis targeted therapies and translation of the potential findings into clinical treatment are of great significance.
作者
曾志萍
郭津生
Zhi-Ping Zeng Jin-Sheng Guo(Department of Gastroenterology, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, Chin)
出处
《世界华人消化杂志》
CAS
2017年第7期569-575,共7页
World Chinese Journal of Digestology
基金
上海市浦江人才计划基金资助项目
No.09PJ402600
国家自然科学基金资助项目
Nos.91129705
81070340~~
关键词
肝纤维化
机制
治疗靶点
Liver fibrosis
Mechanisms
Therapeutic targets
